Evidence map›Paper›PMID 30932019›Full record

ArticleModern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc2019

In situ growth in early lung adenocarcinoma may represent precursor growth or invasive clone outgrowth-a clinically relevant distinction.

David Allan Moore, Marco Sereno, Madhumita Das, Juvenal Dario Baena Acevedo, Samantha Sinnadurai, Claire Smith, Abi McSweeney, Xiaoyu Su, Leah Officer, Carolyn Jones and 5 more

Open access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 35 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Genomic Staging of Multifocal Lung Squamous Cell Carcinomas Is Independent of the Comprehensive Morphologic Assessment.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2024
    Article
  8. Article
  9. [Recent Advances in Diagnosis and Treatment Strategies for Multiple Primary Lung Cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2023
    Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 1 country.

David Allan MooreUniversity College London Cancer Institute, 72 Huntley Street, London, WC1E 6HX, UK.
Marco SerenoMRC Toxicology Unit, University of Cambridge, Leicester, LE1 7HB, UK.
Madhumita DasMRC Toxicology Unit, University of Cambridge, Leicester, LE1 7HB, UK.
Juvenal Dario Baena AcevedoLeicester Cancer Research Centre, University of Leicester, Leicester, LE2 7LX, UK.
Samantha SinnaduraiLeicester Cancer Research Centre, University of Leicester, Leicester, LE2 7LX, UK.
Claire SmithMRC Toxicology Unit, University of Cambridge, Leicester, LE1 7HB, UK.ORCID http://orcid.org/0000-0002-6401-2014
Abi McSweeneyLeicester Cancer Research Centre, University of Leicester, Leicester, LE2 7LX, UK.
Xiaoyu SuLeicester Cancer Research Centre, University of Leicester, Leicester, LE2 7LX, UK.
Leah OfficerMRC Toxicology Unit, University of Cambridge, Leicester, LE1 7HB, UK.
Carolyn JonesMRC Toxicology Unit, University of Cambridge, Leicester, LE1 7HB, UK.
Kate DudekMRC Toxicology Unit, University of Cambridge, Leicester, LE1 7HB, UK.
David GutteryLeicester Cancer Research Centre, University of Leicester, Leicester, LE2 7LX, UK.
Phillipe TaniereCellular Pathology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, B15 2TH, UK.
Ruth V SpriggsMRC Toxicology Unit, University of Cambridge, Leicester, LE1 7HB, UK.
John Le QuesneMRC Toxicology Unit, University of Cambridge, Leicester, LE1 7HB, UK. jlq2@le.ac.uk.
University of Leicester · GBUniversity College London Hospitals NHS Foundation Trust · GBUniversity Hospitals Birmingham NHS Foundation Trust · GB

Funding

Cancer Research UK C1362/A18081Medical Research Council MC_UP_1203/1
6 · The paper itself

Abstract

The switch from in situ to invasive tumor growth represents a crucial stage in the evolution of lung adenocarcinoma. However, the biological understanding of this shift is limited, and 'Noguchi Type C' tumors, being early lung adenocarcinomas with mixed in situ and invasive growth, represent those that are highly valuable in advancing our understanding of this process. All Noguchi Type C adenocarcinomas (n = 110) from the LATTICE-A cohort were reviewed and two patterns of in situ tumor growth were identified: those deemed likely to represent a true shift from precursor in situ to invasive disease ('Noguchi C1') and those in which the lepidic component appeared to represent outgrowth of the invasive tumor along existing airspaces ('Noguchi C2'). Overall Ki67 fraction was greater in C2 tumors and only C1 tumors showed significant increasing Ki67 from in situ to invasive disease. P53 positivity was acquired from in situ to invasive disease in C1 tumors but both components were positive in C2 tumors. Likewise, vimentin expression was increased from in situ to invasive tumor in C1 tumors only. Targeted next generation sequencing of 18 C1 tumors identified four mutations private to the invasive regions, including two in TP53, while 6 C2 tumors showed no private mutations. In the full LATTICe-A cohort, Ki67 fraction classified as either less than or greater than 10% within the in situ component of lung adenocarcinoma was identified as a strong predictor of patient outcome. This supports the proposition that tumors of all stages that have 'high grade' in situ components represent those with aggressive lepidic growth of the invasive clone. Overall these data support that the combined growth of Noguchi C tumors can represent two differing biological states and that 'Noguchi C1' tumors represent the genuine biological shift from in situ to invasive disease.

Indexed as

Cell ProliferationAdenocarcinoma of LungAdultAgedAged, 80 and overBiomarkers, TumorCarcinoma in SituFemaleHumansKi-67 AntigenLung NeoplasmsMaleMiddle AgedMutationNeoplasm GradingNeoplasm InvasivenessBiomarkers, TumorKi-67 AntigenMKI67 protein, humanTP53 protein, humanTumor Suppressor Protein p53VimentinVIM protein, human

Identifiers

PMID30932019
OpenAlexW2935193238

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.